FILTER

Refine your search with the following facets to narrow down your results.

454 Current news about the topic metabolic diseases

ASINEX Ltd and Biovitrum announce a 3 year drug discovery collaboration

25-Nov-2004 - ASINEX Ltd and Biovitrum AB have entered into a drug discovery and development collaboration. During the initial three years of the collaboration, drug discovery activities will be focused on finding and optimizing leads suitable for advancing into pre-clinical development for multiple targets ...

Biovitrum computational chemistry drug discovery collaborations +4

Microchip Biotechnologies Awarded $6.1M Grant to Build Next-Generation DNA Sequencer

12-Nov-2004 - Microchip Biotechnologies Inc. (MBI) has been awarded a $6.1 million grant from the National Human Genome Research Institute (NHGRI) to develop an innovative nanofluidic technological platform that promises to dramatically reduce the cost of DNA sequencing. The grant was the largest in a series ...

Amersham Biosciences Bio-Medical Research business development +19

Merck KGaA restructured its pharmaceuticals business in Germany

02-Nov-2004 - Darmstadt - Merck KGaA has restructured its pharmaceuticals business in Germany. The business with ethicals, which formerly operated as Merck Pharma Germany as a part of Merck KGaA, has been transferred into a legally self-standing company as of November 1, 2004. The new Merck Pharma GmbH ...

cardiovascular diseases diabetes diseases +3

Biovitrum AB and Pharmacopeia form strategic drug discovery and development alliance

02-Nov-2004 - Stockholm and Princeton. Biovitrum AB and Pharmacopeia Drug Discovery, Inc. announced that they have entered into a multi-year drug discovery and development alliance. Biovitrum and Pharmacopeia will work together to identify and optimise small molecule lead compounds suitable for advancing into ...

biology Biovitrum chemistry +4

ASU gets grant to develop high speed DNA sequence reader

01-Nov-2004 - Sequencing of the human genome is one of the major scientific advances of our time. But with 3 billion base pairs, initial sequencing of the human genome took 11 years and cost $1 billion to complete in 2002. Today, it costs up to $50 million to sequence 3 billion base pairs. That may soon ...

bases biochemistry chemistry +9

Naturally-occurring, Plant-based Compounds Lead Researchers Toward New Treatments for Type 2 Diabetes

05-Oct-2004 - Chicago. Scientists from MitoChroma(R) Research, Inc., a privately-held pharmaceutical development company, recently announced a patent-pending discovery that could complement current medical management modalities for Type 2 Diabetes, insulin resistance and the set of related conditions called ...

cardiovascular diseases glucose glucose metabolism +3

Biovitrum acquires promising anti-obesity drug leads from BioFocus

24-Sep-2004 - Chesterford Research Park, UK and Stockholm, Sweden. BioFocus plc., a world leader in drug discovery, and Biovitrum today announce that Biovitrum has acquired from BioFocus the rights to a promising research project in obesity. The research project, which currently is at the end of the lead ...

atherosclerosis Biovitrum business development +9

Global Genomics ab signs collaboration agreement with Rheoscience A/S

22-Sep-2004 - Global Genomics(SM) AB (Stockholm, Sweden) announced today that Rheoscience A/S (Roedovre, Denmark) has entered into an agreement for the use tangerine® gene expression profiling to study targets in metabolic diseases. Ulf Boberg, CEO at Global Genomics stated, "This agreement is yet another ...

bases Denmark Expression +9

Marathoning Mice Could Have Olympian Effects on Obesity

25-Aug-2004 - A molecular switch known to regulate fat metabolism appears to prevent obesity and turns laboratory mice into marathon runners, a Salk Institute study has found. The discovery of the switch could lead to treatments for obesity and disorders associated with it, such as heart disease and type 2 ...

biology birth defects cardiovascular diseases +8

Medivir and Biovitrum Initiate Research Collaboration in Diabetes

19-Jul-2004 - Medivir and Biovitrum announce that they initiate a research collaboration to meet the significant and growing medical need in type 2 diabetes. The intent of the collaboration is to combine the strengths of the two companies and develop a candidate drug for type 2 diabetes. Biovitrum is ...

Biovitrum cooperations Medivir +3